Role of skin enzymes in metabolism of topical drugs

Abstract

Topical drugs have gained a lot of interest with their massive market growth and are available in various dosage forms. Prodrug compounds of transdermal delivery systems can be very different and designed to convert into the form of active pharmaceutical ingredients (APIs) through enzymatic action once they enter the body. The skin, as an interfacial barrier between the body and surroundings, has demonstrated critical roles in metabolizing, filtering, and detoxifying to minimize certain side effects and improve the medication benefits of topically administered products. It is well recognized that the drug pharmacokinetics can be altered by the presence of skin enzymes driven by biotransformation reactions. To evaluate the effectiveness of a topical generic drug product, its safety, and bioequivalence with the reference one, models assessing enzyme metabolic activity are highly required for testing the amount of drugs that are metabolized or can potentially be metabolized in both healthy and compromised skin. Thus, knowledge of skin composition and enzyme expression levels is of paramount importance in mapping the relevant metabolism that may have occurred. Regulatory authorities have also been making efforts to develop efficient and harmonizable protocols to evaluate the metabolism of transdermal products. This review is a compilation of reported skin metabolizing enzymes, including their role in both drug metabolism and homeostasis regulation, along with their localization and quantification in skin equivalents (and/or membrane layers). Various aspects that potentially affect the skin enzyme metabolism study were also discussed with respect to drug development considerations.

Keywords

Topical drugs / skin enzymes / metabolism / drug-metabolizing enzymes / homeostasis / skin models / vitamins / drug development

References

[1] Global topical drug delivery market (2023-2028) by products, routes of administration, end-user, and geography, competitive analysis, impact of covid-19 with ansoff analysis. Available from: https://www.researchandmarkets.com/reports/5696819/global-drug-delivery-devices-market-2023-2028. [Last accessed on 10 Sep 2024]

[2] Topical drug delivery - global strategic business report. Available from: https://www.researchandmarkets.com/reports/5303550/topical-drug-delivery-global-strategic. [Last accessed on 10 Sep 2024]

[3] Raina N,Thakur VK.New insights in topical drug delivery for skin disorders: from a nanotechnological perspective.ACS Omega19;8:19145-167. PMCID:PMC10249123

[4] Buhse L,Westenberger B.Topical drug classification.Int J Pharm2005;295:101-12.

[5] Hmingthansanga V,Banerjee S,Velayutham R.Improved topical drug delivery: role of permeation enhancers and advanced approaches.Pharmaceutics2022;14:2818. PMCID:PMC9785322

[6] Eilstein J,Arbey E,Wilkinson S.Xenobiotic metabolizing enzymes in human skin and SkinEthic reconstructed human skin models.Exp Dermatol2015;24:547-9.

[7] Wiegand C,Merk HF.Dermal xenobiotic metabolism: a comparison between native human skin, four in vitro skin test systems and a liver system.Skin Pharmacol Physiol2014;27:263-75.

[8] Couto N,Russo C.Label-free quantitative proteomics and substrate-based mass spectrometry imaging of xenobiotic metabolizing enzymes in ex vivo human skin and a human living skin equivalent model.Drug Metab Dispos2021;49:39-52.

[9] Leake CD.Annual review of pharmacology and toxicology: review of reviews.Annu Rev Pharmacol Toxicol1978;18:581-8.

[10] Almeida M.Human enhancement: genetic engineering and evolution.Evol Med Public Health2019;2019:183-9. PMCID:PMC6788211

[11] D’Orazio J,Amaro-Ortiz A.UV radiation and the skin.Int J Mol Sci2013;14:12222-48. PMCID:PMC3709783

[12] Steinhoff M,Ahmad A,Buddenkotte J.Targeting oncogenic transcription factors in skin malignancies: an update on cancer stemness and therapeutic outcomes.Semin Cancer Biol2022;87:98-116.

[13] Simpson CL,Green KJ.Deconstructing the skin: cytoarchitectural determinants of epidermal morphogenesis.Nat Rev Mol Cell Biol2011;12:565-80. PMCID:PMC3280198

[14] Kolarsick PAJ,Goodwin C.Anatomy and physiology of the skin.J Dermat Nurses Asso2011;3:203-13.

[15] Oesch F,Oesch-Bartlomowicz B,Landsiedel R.Drug-metabolizing enzymes in the skin of man, rat, and pig.Drug Metab Rev2007;39:659-98.

[16] Oesch F,Landsiedel R.Xenobiotica-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models.Arch Toxicol2018;92:2411-56. PMCID:PMC6063329

[17] Baron JM,Schiffer R.Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes.J Invest Dermatol2001;116:541-8.

[18] Pyo SM.Maibach, skin metabolism: relevance of skin enzymes for rational drug design.Skin Pharmacol Physiol2019;32:283-94.

[19] Rekka EA,Pantelidou M.Xenobiotic metabolising enzymes: impact on pathologic conditions, drug interactions and drug design.Curr Top Med Chem2019;19:276-91.

[20] Ahmad N.Cytochrome p450: a target for drug development for skin diseases.J Invest Dermatol2004;123:417-25.

[21] Rendic S.Guengerich, survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals.Chem Res Toxicol2015;28:38-42. PMCID:PMC4303333

[22] Neis MM,Wiederholt T.Expression and induction of cytochrome P450 isoenzymes in human skin equivalents.Skin Pharmacol Physiol2010;23:29-39.

[23] Slominski RM,Elmets C,Slominski AT.The significance of CYP11A1 expression in skin physiology and pathology.Mol Cell Endocrinol2021;530:111238. PMCID:PMC8205265

[24] Slominski A,Zjawiony J.The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism.FEBS J2005;272:4080-90. PMCID:PMC2234577

[25] Slominski AT,Janjetovic Z.Biological effects of CYP11A1-derived Vitamin D and lumisterol metabolites in the skin.J Invest Dermatol2024;11:S0022-202X(24)00386

[26] Slominski AT,Kim TK.Novel activities of CYP11A1 and their potential physiological significance.J Steroid Biochem Mol Biol2015;151:25-37. PMCID:PMC4757911

[27] van Eijl S,Cupitt J.Elucidation of xenobiotic metabolism pathways in human skin and human skin models by proteomic profiling.PLoS One2012;7:e41721. PMCID:PMC3406074

[28] Di L,Jordan S.The role of alcohol dehydrogenase in drug metabolism: beyond ethanol oxidation.AAPS J2021;23:20.

[29] Muzio G,Paiuzzi E,Canuto RA.Aldehyde dehydrogenases and cell proliferation.Free Radic Biol Med2012;52:735-46.

[30] Xia J,Liu S.Aldehyde dehydrogenase in solid tumors and other diseases: potential biomarkers and therapeutic targets.MedComm (2020)2023;4:e195. PMCID:PMC9842923

[31] Manevski N,Bertschi B.Aldehyde oxidase activity in fresh human skin.Drug Metab Dispos2014;42:2049-57.

[32] Barski OA,Bhatnagar A.Bhatnagar, the aldo-keto reductase superfamily and its role in drug metabolism and detoxification.Drug Metab Rev2008;40:553-624. PMCID:PMC2663408

[33] Wu W,Lin H.The specific binding and promotion effect of azoles on human aldo-keto reductase 7A2.Metabolites2023;13:601. PMCID:PMC10221418

[34] Lee A,Saeed SR.Topical azole treatments for otomycosis.Cochrane Database Syst Rev2021;5:Cd009289. PMCID:PMC8147581

[35] Shi SM.The role of carbonyl reductase 1 in drug discovery and development.Expert Opin Drug Metab Toxicol2017;13:859-70.

[36] Kapelyukh Y,Scheer N.Defining the contribution of CYP1A1 and CYP1A2 to Drug metabolism using humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 knockout mice.Drug Metab Dispos2019;47:907-18. PMCID:PMC6657216

[37] Li F,Gonzalez FJ.Gonzalez, potential role of CYP1B1 in the development and treatment of metabolic diseases.Pharmacol Ther2017;178:18-30. PMCID:PMC5600638

[38] Hedrich WD,Wang H.Insights into CYP2B6-mediated drug-drug interactions.Acta Pharm Sin B2016;6:413-25. PMCID:PMC5045548

[39] Szymański Ł,Palusińska M.Retinoic acid and its derivatives in skin.Cells2020;9:2660. PMCID:PMC7764495

[40] Hakkola J,Turpeinen M.Inhibition and induction of CYP enzymes in humans: an update.Arch Toxicol2020;94:3671-722. PMCID:PMC7603454

[41] Nebert DW,Miller WL.Human cytochromes P450 in health and disease.Philos Trans R Soc Lond B Biol Sci2013;368:20120431. PMCID:PMC3538421

[42] Tuckey RC,Slominski AT.Slominski, the serum vitamin d metabolome: what we know and what is still to discover.J Steroid Biochem Mol Biol2019;186:4-21. PMCID:PMC6342654

[43] O’Byrne SM.Retinol and retinyl esters: biochemistry and physiology.J Lipid Res2013;54:1731-43. PMCID:PMC3679378

[44] Gottfried E,Hahn J,Andreesen R.Monocyte-derived cells express CYP27A1 and convert vitamin D3 into its active metabolite.Biochem Biophys Res Commun2006;349:209-13.

[45] Bikle DD.Vitamin D metabolism and function in the skin.Mol Cell Endocrinol2011;347:80-9. PMCID:PMC3188673

[46] Lepesheva GI.Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms.Biochim Biophys Acta2007;1770:467-77. PMCID:PMC2324071

[47] Lepesheva GI,Kleshchenko Y,Villalta F.CYP51: a major drug target in the cytochrome P450 superfamily.Lipids2008;43:1117-25. PMCID:PMC2715142

[48] Guo H,Wang Y.Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib.Cell Death Dis2022;13:623. PMCID:PMC9293983

[49] Phillips IR.Drug metabolism by flavin-containing monooxygenases of human and mouse.Expert Opin Drug Metab Toxicol2017;13:167-181.

[50] Fukami T,Nakajima M.Non-P450 drug-metabolizing enzymes: contribution to drug disposition, toxicity, and development.Annu Rev Pharmacol Toxicol2022;62:405-25.

[51] Gautheron J.The multifaceted role of epoxide hydrolases in human health and disease.Int J Mol Sci2020;22:13. PMCID:PMC7792612

[52] Rižner TL.The important roles of steroid sulfatase and sulfotransferases in gynecological diseases.Front Pharmacol2016;7:30. PMCID:PMC4757672

[53] Marchais-Oberwinkler S,Möller G.17β-hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.J Steroid Biochem Mol Biol2011;125:66-82.

[54] Götz C,Tigges J.Xenobiotic metabolism capacities of human skin in comparison with a 3D epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: activating enzymes (Phase I).Exp Dermatol2012;21:358-63.

[55] Federici L,Pezzola S.Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases.Cancer Res2009;69:8025-34.

[56] Zhou H,Liu D,Oakley AJ.Structural insights into the dehydroascorbate reductase activity of human omega-class glutathione transferases.J Mol Biol2012;420:190-203.

[57] Patskovsky Y,Almo SC.Transition state model and mechanism of nucleophilic aromatic substitution reactions catalyzed by human glutathione S-transferase M1a-1a.Biochemistry2006;45:3852-62.

[58] Tars K,Shokeer A,Mannervik B.Structural basis of the suppressed catalytic activity of wild-type human glutathione transferase T1-1 compared to its W234R mutant.J Mol Biol2006;355:96-105.

[59] Gamage N,Hempel N.Human sulfotransferases and their role in chemical metabolism.Toxicol Sci2006;90:5-22.

[60] Wang FY,Zhao DF.Analytical methodologies for sensing catechol-O-methyltransferase activity and their applications.J Pharm Anal2021;11:15-27. PMCID:PMC7930641

[61] Rao SP,Bellamkonda H.Role of 3-mercaptopyruvate sulfurtransferase (3-MST) in physiology and disease.Antioxidants (Basel)2023;12:603. PMCID:PMC10045210

[62] Chermnykh ES,Vorotelyak EA.Vorotelyak, transglutaminase 3: the involvement in epithelial differentiation and cancer.Cells2020;9:1996. PMCID:PMC7563467

[63] Lee M,Bang D.Thiopurine S-methyltransferase polymorphisms in korean dermatologic patients.Ann Dermatol2017;29:529-35. PMCID:PMC5597644

[64] Kruithof PD,Aguilar Lozano SP.Unraveling the role of thiosulfate sulfurtransferase in metabolic diseases.Biochim Biophys Acta Mol Basis Dis2020;1866:165716.

[65] Kazem S,Gibbs S.Skin metabolism phase I and phase II enzymes in native and reconstructed human skin: a short review.Drug Discov Today2019;24:1899-1910.

[66] Hu T,Hayden PJ.Xenobiotic metabolism gene expression in the EpiDerm™ in vitro 3D human epidermis model compared to human skin.Toxicology in Vitro2010;24:1450-63.

[67] Janmohamed A,Phillips IR.Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450.Biochem Pharmacol2001;62:777-86.

[68] Shimizu Y,Yonekawa E.Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury.J Toxicol Sci2021;46:167-76.

[69] Hewitt NJ,Fritsche E.Use of human in vitro skin models for accurate and ethical risk assessment: metabolic considerations.Toxicol Sci2013;133:209-17.

[70] Ściskalska M.The role of GSTπ isoform in the cells signalling and anticancer therapy.Eur Rev Med Pharmacol Sci2020;24:8537-50.

[71] Lockley DJ,Williams FM.Cutaneous metabolism of glycol ethers.Arch Toxicol2005;79:160-8.

[72] Liu M,Wang Y.Non-invasive proteome-wide quantification of skin barrier-related proteins using label-free LC-MS/MS analysis.Mol Med Rep2020;21:2227-35. PMCID:PMC7115193

[73] Candi E,Paradisi A.Expression of transglutaminase 5 in normal and pathologic human epidermis.J Invest Dermatol2002;119:670-7.

[74] Tokudome Y,Hashimoto F.Esterase activity and intracellular localization in reconstructed human epidermal cultured skin models.Ann Dermatol2015;27:269-74. PMCID:PMC4466279

[75] Lau WM,Sakenyte K.Distribution of esterase activity in porcine ear skin, and the effects of freezing and heat separation.Int J Pharm2012;433:10-15.

[76] Telaprolu KC,Mohammed YH.Human skin drug metabolism: relationships between methyl salicylate metabolism and esterase activities in ivpt skin membranes.Metabolite2023;13:934. PMCID:PMC10456861

[77] Eilstein J,Budimir N,Wilkinson S.Comparison of xenobiotic metabolizing enzyme activities in ex vivo human skin and reconstructed human skin models from SkinEthic.Arch Toxicol2014;88:1681-94.

[78] Lefèvre-Utile A,Haftek M.Five functional aspects of the epidermal barrier.Int J Mol Sc2021;22:11676. PMCID:PMC8583944

[79] Redoules D,Périé J.Epidermal enzymes: their role in homeostasis and their relationships with dermatoses.Skin Pharmacol Appl Skin Physiol1998;11:183-92.

[80] Nauroy P.Kallikreins: essential epidermal messengers for regulation of the skin microenvironment during homeostasis, repair and disease.Matrix Biol Plus2020;6-7:100019. PMCID:PMC7852331

[81] Tabolacci C,Provenzano B.Evidences for a role of protein cross-links in transglutaminase-related disease.Amino Acids2012;42:975-86.

[82] Wu Z,Meyer-Hoffert U,Schröder JM.Molecular identification and expression analysis of filaggrin-2, a member of the S100 fused-type protein family.PLoS One2009;4:e5227. PMCID:PMC2668185

[83] Lukić M,Savić SD.Towards optimal ph of the skin and topical formulations: from the current state of the art to tailored products.Cosmetics2021;8:69.

[84] Slominski AT,Skobowiat C,Slominski RM.Introduction, in sensing the environment: regulation of local and global homeostasis by the skin’s neuroendocrine system.Adv Anat Embryol Cell Biol2012;212:1-115. PMCID:PMC3422784

[85] Veith A.Role of cytochrome P450s in the generation and metabolism of reactive oxygen species.Curr Opin Toxicol2018;7:44-51. PMCID:PMC5841237

[86] Slominski RM,Raman C.Photo-neuro-immuno-endocrinology: how the ultraviolet radiation regulates the body, brain, and immune system.Proc Natl Acad Sci U S A2024;121:e2308374121. PMCID:PMC10998607

[87] Slominski AT,Semak I.Melatonin, mitochondria, and the skin.Cell Mol Life Sci2017;74:3913-25 PMCID:PMC5693733

[88] Slominski AT,Slominski RM.Melatonin and its metabolites can serve as agonists on the aryl hydrocarbon receptor and peroxisome proliferator-activated receptor gamma.Int J Mol Sci2023;24:15496. PMCID:PMC10607054

[89] Slominski AT,Plonka PM,Paus R.How UV light touches the brain and endocrine system through skin, and why.Endocrinology2018;159:1992-2007. PMCID:PMC5905393

[90] Slominski A,Shibahara S.Melanin pigmentation in mammalian skin and its hormonal regulation.Physiol Rev2004;84:1155-228.

[91] Slominski A,Pawelek J.L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions.Pigment Cell Melanoma Res2012;25:14-27. PMCID:PMC3242935

[92] Karkoszka M,Wrzesniok D.Melanin biopolymers in pharmacology and medicine-skin pigmentation disorders, implications for drug action, adverse effects and therapy.Pharmaceuticals (Basel)2024;17:521. PMCID:PMC11054731

[93] Slominski RM,Janjetovic Z.Malignant melanoma: an overview, new perspectives, and Vitamin D signaling.Cancers (Basel)2024;16:2262. PMCID:PMC11201527

[94] Feingold KR.Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis.J Lipid Res2007;48:2531-46.

[95] Jaffri J. Reactive oxygen species and antioxidant system in selected skin disorders.Malays J Med Sci2023;30:7-20. PMCID:PMC9984103

[96] Palikhe NS,Nam YH,Park HS.Polymorphisms of aspirin-metabolizing enzymes CYP2C9, NAT2 and UGT1A6 in aspirin-intolerant urticaria.Allergy Asthma Immunol Res2011;3:273-6. PMCID:PMC3178826

[97] Alyami MH,Alshehri AA,Shaikh IA.Tamoxifen citrate containing topical nanoemulgel prepared by ultrasonication technique: formulation design and in vitro evaluation.Gels2022;8:456. PMCID:PMC9316521

[98] Soares-Lopes LR,Filho LL,da Silva BB.Morphological and morphometric analysis of the effects of intralesional tamoxifen on keloids.Exp Biol Med (Maywood)2017;242:926-9. PMCID:PMC5407593

[99] Machado V,Medeiros R.Hyaluronic acid-based nanomaterials applied to cancer: where are we now?.Pharmaceutics2022;14:2092. PMCID:PMC9609123

[100] Zhao J.Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention.Carcinogenesis1999;20:2101-8.

[101] Singh RP.Cosmeceuticals and silibinin.Clinics in Dermatology2009;27:479-84. PMCID:PMC2767273

[102] Romanucci V,Pagano R.Investigation on the solid-phase synthesis of silybin prodrugs and their timed-release.Bioorg Med Chem2021;50:116478.

[103] Karami M, Sharif Makhmalzadeh B, Pooranian M, Rezai A. Preparation and optimization of silibinin-loaded chitosan-fucoidan hydrogel: an in vivo evaluation of skin protection against UVB.Pharm Dev Technol2021;26:209-19.

[104] Bell M,Naylor C.Discovery of soft-drug topical tool modulators of sphingosine-1-phosphate receptor 1 (S1PR1).ACS Med Chem Lett2019;10:341-7.

[105] Aprile S,Pirali T.Soft drugs for dermatological applications: recent trends.Drug Discovery Today2019;24:2234-46.

[106] Tom WL,Chanda S.Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study.Pediatr Dermatol2016;33:150-9.

[107] Kim D,Sheu M.Noncoding dsRNA induces retinoic acid synthesis to stimulate hair follicle regeneration via TLR3.Nat Commun2019;10:2811. PMCID:PMC6594970

[108] Gudas LJ.Retinoid metabolism: new insights.J Mol Endocrinol2022;69:T37-49. PMCID:PMC9561048

[109] Stresser DM,Hewitt P.Towards in vitro models for reducing or replacing the use of animals in drug testing.Nat Biomed Eng2024;8:930-5. PMCID:PMC10180184

[110] Cobbina E.Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.Drug Metab Rev2017;49:197-211. PMCID:PMC5576152

[111] Bhutani P,Raja N.U.S. FDA approved drugs from 2015-June 2020: a perspective.J Med Chem2021;64:2339-81.

[112] Sumantran VN,Bera R.Microarray analysis of differentially-expressed genes encoding CYPs and phase II drug metabolizing enzymes in psoriasis and melanoma.Pharmaceutics2016;8:4. PMCID:PMC4810080

[113] Perihan O,Neslihan D.The activity of adenosine deaminase and oxidative stress biomarkers in scraping samples of acne lesions.J Cosmet Dermatol2012;11:323-8.

[114] Visconti B,Carotti S.Immunohistochemical expression of VDR is associated with reduced integrity of tight junction complex in psoriatic skin.J Eur Acad Dermatol Venereol2015;29:2038-42.

[115] Ortiz-Lopez LI,Bollag WB.Updated perspectives on keratinocytes and psoriasis: keratinocytes are more than innocent bystanders.Psoriasis (Auckl)2022;12:73-87. PMCID:PMC9075909

[116] Danso M,van Drongelen V.Altered expression of epidermal lipid bio-synthesis enzymes in atopic dermatitis skin is accompanied by changes in stratum corneum lipid composition.J Dermatol Sci2017;88:57-66.

[117] Boniface K,Picardo M.Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy.Clin Rev Allergy Immunol2018;54:52-67.